Updated annually, the British Pharmacopoeia (BP) is the only comprehensive collection of authoritative official standards for UK pharmaceutical substances and medicinal products.

It includes approximately 4,000 monographs which are legally enforced by the Human Medicines Regulations 2012. Medicinal products or active pharmaceutical ingredients sold or supplied in the UK must comply with the relevant monograph.

All monographs and requirements of the European Pharmacopoeia (Ph. Eur.) are reproduced in the BP, making the BP a convenient and fully comprehensive set of standards that can be used across Europe and beyond.

New for the BP 2024
The BP 2024 supersedes the BP 2023 and becomes legally effective on 1 January 2024. This edition incorporates new monographs from both the BP and Ph. Eur. along with a significant number of revised monographs.

• 27 new BP monographs, 17 new Ph. Eur. monographs.
• 93 amended BP monographs.
• All monographs from the Ph. Eur. 11th edition
• Ph. Eur. supplements 11.4 to 11.6 included as in-year online and download product updates
• We are updating the BP website to improve your experience of using the site.
  Updated features for the 2024 edition include:
  • A fresh and user-friendly site design, coupled with improved navigation
  • Enhanced purchasing journeys for a seamless experience
  • Enhanced layout allows you to search and find the monographs you need
  • Advanced in-publication search functionality
  • A revamped timeline and tracked changes feature, enabling you to track the evolution of monographs over time

This licence is based on the number of concurrent users and will offer the customer:

• One year of access to BP 2024 online + BP archive from BP 2014
• Access across all sites in one country only
• Subscriptions run from 1 August
  • New customers may pay a pro-rata cost should they wish to subscribe after the 1 August
• Access by IP recognition or username and password (although IP is preferred)
• Does not include subsidiaries or affiliates of the customer
• Fixed concurrency based on size of licence